Background. There are contradictory data about the influence that hepatitis C virus (HCV) has on immune activation and inflammation in patients coinfected with human immunodeficiency virus (HIV) and HCV.
Morbidity and mortality due to hepatitis C virus (HCV) infection have exceeded mortality due to human immunodeficiency virus (HIV) infection in recent years among HIV/HCVcoinfected patients [1, 2] . Sustained virological response (SVR) is associated with a >70% reduction in the risk of hepatocellular carcinoma and a 90% reduction in the risk of liver-related mortality and has substantially improved the quality of life in both HCV-monoinfected and HIV-coinfected patients [3] [4] [5] . However, because of the high cost of novel treatments for HCV infection, therapy continues to focus on fibrosis and is recommended only for patients with liver fibrosis stage ≥2 [6] .
On the other hand, immune activation and inflammation due to HIV infection is currently considered to be the driving force of CD4 + T-cell depletion and of the functional impairment of the immune system that eventually leads to AIDS in patients who do not receive antiretroviral therapy (ART) [7, 8] . Although ART reduces levels of both cellular and soluble activation markers, it fails to completely control immune activation and inflammation, despite consistent plasma viral load suppression [9] . This immune activation and inflammation also plays a pivotal role in the emergence of serious non-AIDS-defining events (including cardiovascular, renal, liver, neurologic, and bone diseases; non-AIDS-related cancer; and frailty), which have higher rates of morbidity and mortality among HIV-infected patients, compared with the general population [10] [11] [12] [13] [14] . Coinfections with different pathogens, including cytomegalovirus, Epstein-Barr virus, hepatitis B virus, or HCV, has been suggested as contributing to immune activation during HIV infection [15] . Regarding the influence of chronic hepatitis C on immune activation and inflammation in HIV/HCV-coinfected patients, we previously reported a higher level of immune activation on CD4 + and CD8 + T-cells in coinfected subjects [16] ; similar findings were observed in other studies [17] [18] [19] [20] , which compared HIV-monoinfected patients to HIV/HCV-coinfected patients. However, 2 more-recent studies found a similar level immune activation in both groups of patients [21, 22] . In this study, we aimed to evaluate the impact that eradication of HCV has on immune activation and immune recovery in HIV/HCV-coinfected patients.
MATERIALS AND METHODS

Study Population
In this prospective study, we consecutively enrolled HIV/ HCV-coinfected patients who maintained an undetectable HIV RNA level during stable ART and achieved sustained virological response (SVR) with interferon-free hepatitis C treatments at the Infectious Diseases Department of the Virgen del Rocío University Hospital (Seville, Spain) from April to December 2015. SVR was defined as a negative plasma HVC RNA test result 3-6 months after ending anti-HCV therapy. Patients were treated under routine clinical care conditions, according to the prevalent HCV treatment guidelines at the time and the best medical judgment, based on HCV genotype, past history of HCV treatment, drug interactions with ART, and liver fibrosis assessed by transient elastography (FibroScan, Echosens, Paris, France). Cirrhosis was defined as a liver stiffness value of ≥14.5 kPa [23] . The exclusion criteria were hepatitis B virus coinfection, other concomitant causes of liver disease, active infections, and past or present treatment with steroids or immunosuppressive drugs before starting anti-HCV therapy. The study was approved by the Ethics Committee of the Virgen del Rocio University Hospital (protocol code: UCE-VHC-2015-1; internal code: 1050-N-15) and all of the patients provided informed consent.
End Points, Follow-up, and Laboratory Methods
The primary end point was the change in immune activation, measured by the expression of HLA-DR and CD38 in both CD4 + and CD8 + T cells, 1 month after completing anti-HCV therapy. Secondary end points were changes in expression of PD-1 and CD57 in both CD4 + and CD8 + T cells, activation of monocytes-macrophages, levels of soluble markers of inflammation, levels of markers of microbial translocation, and the level of proviral HIV DNA in peripheral blood mononuclear cells (PBMCs). Additionally, we measured changes in the CD4 + T-cell count and the ratio of the CD4 + T-cell count to the CD8 + T-cell count (hereafter, the CD4 + /CD8 + T-cell ratio) 1 and 6 months after ending anti-HCV therapy. Additionally, a control group of healthy volunteers was included in the analysis as reference.
Patients were assessed at baseline, after 1 month of anti-HCV therapy, at the end of treatment, and 1 month later, and data including adverse events, biochemical profiles, and hematologic counts were recorded. The HCV RNA level was measured at baseline, at the end of anti-HCV therapy, and 3-6 months later, using a quantitative polymerase chain reaction (PCR) assay (the Cobas TaqMan test; Roche Diagnostic Systems, Pleasanton, CA; detection limit, 15 IU/mL). The HIV RNA level (determined by the Cobas AmpliPrep/Cobas TaqMan HIV-1 Test, version 2.0; lower detection limit, 15 copies/mL) and CD4 + and CD8 + T-cell counts (determined by standard flow cytometry) were measured at baseline, at the end of anti-HCV therapy, and 1 and 6 months later.
The activation was assessed in both CD4 + and CD8 + T cells by flow cytometry, using the expression markers 7AAD PerCp-Cy5.5 (NA), CD3 BV786 (UCHT1), CD4 APC-Cy7 (RPA-T4), CD8 BV510 (SK1), HLADR FITC (G46-6), and CD38 BV605 (HB7), and senescence and cell dysfunction were measured using the antibodies CD57 APC (NK-1) and PD-1 PE (EH12.1), respectively (all from BD Biosciences, San Diego, CA). The stained samples were acquired on a Fortessa LSR II instrument (BD Biosciences, Madrid, Spain) and analyzed with the software FACSDiva (BD Biosciences). All analyses were performed on cryopreserved PBMCs. The cell viability was >80% in all samples, and dead cells were discarded from the analysis. Plasma samples were assessed by commercially available enzyme-linked immunosorbent assay (ELISA) kits for determination of interleukin 6 (IL-6) levels (using the QuantiGlo IL-6 immunoassay; R&D Systems, Minneapolis, MN), high-sensitivity C-reactive protein (hs-CRP) levels (using the High Sensitive C Reactive Protein ELISA kit [catalog no. SK00080-02]; Aviscera Bioscience, Santa Clara, CA), D-dimer levels (using the Human D-Dimer test; Thermo Fisher Scientific, Waltham, MA), and soluble CD14 (sCD14) levels (using the Human sCD14 Quantikine ELISA kit; R&D Systems, Abingdon, United Kingdom) according to the manufacturers' instructions. Microbial translocation was assessed by measuring 2 different markers: bacterial lipopolysaccharide (LPS) levels, by using the QCL-1000 Limulus Amebocyte Lysate kit (Lonza, Basel, Switzerland); and plasma 16S ribosomal DNA concentrations, by means of quantitative PCR analysis with degenerate forward and reverse primers (8F: 5′-AGAGTTTGATYMTGGCTCAG-3′; and 361R: 5′-CGYCCATTGBGBAADATTCC-3′) and a TaqMan probe (338P: 5′-FAM-TACGGGAGGCAGCAGT-BHQ1-3′) [24] .
Total cellular HIV DNA (integrated and unintegrated viral DNA) from PBMCs was assayed by using a custom TaqMan-based real-time PCR assay for the amplification of nucleotides 761-861 in the long terminal repeat of the HIV gag region, which is highly conserved (91%) among all HIV-1 group M subtypes, using 2 specific primers (forward: 5′-TAGCGGAGGCTAGAAGGAGA-3′; and reverse: 5′-CCCTGGCCTTAACCGAATT-3′) and a probe within the selected gag long terminal repeat region (5′-TACCGACGCTCTCGCACCCA-3′) labeled with FAM, as previously described [25] .
Statistical Analysis
Results are expressed as median values, with interquartile ranges (IQRs) or ranges, for continuous variables, and as numbers and percentages of cases, for categorical variables. The χ 2 and Fisher exact tests were used to compare categorical variables, and the Mann-Whitney U test was used to compare quantitative variables. The relationships between continuous variables were assessed by Spearman rank correlation coefficients (determined using the ρ test). The Wilcoxon signed rank test was performed to compare changes in continuous variables over time. The variables that were statistically significant in the univariate analysis were included in a logistic regression model. Differences were considered statistically significant if the P value was < .05, after adjustment for multiple comparisons when applicable. The statistical analyses were performed using IBM software (SPSS, version 23.0; SPSS, Chicago, IL).
RESULTS
Patients' Characteristics
A total of 105 white HIV-1/HCV-coinfected patients completed a 12-week course of treatment with anti-HCV direct-acting antiviral agents from April through December 2015. Three subjects did not achieve SVR, 2 were lost to follow-up, and 3 did not maintain an undetectable HIV RNA level. Thus, 97 subjects were included in the analysis, with main baseline characteristics are shown in Table 1 . At baseline, there were no differences among patients with liver fibrosis stages 0-3, and therefore they were grouped together; however, patients with liver cirrhosis had a somewhat lower CD4 + T-cell count, higher expression of CD38 in both CD4 + and CD8 + T cells, and higher levels of LPS and IL-6 than patients without cirrhosis. Forty-five subjects were naive to HCV treatment, and 52 were treated previously (40 received pegylated interferon alfa-2a plus ribavirin, 3 received pegylated interferon alfa-2a plus ribavirin plus telaprevir, 1 received ombitasvir/paritaprevir/ritonavir plus ribavirin, and 1 received sofosbuvir plus ribavirin), with no significant differences in baseline characteristics between the 2 groups (Supplementary Table 1 ). The direct-acting antiviral agents received by the patients were heterogeneous: 36 received sofosbuvir plus ledipasvir, with or without ribavirin; 26 received ombitasvir, paritaprevir/ritonavir, and dasabuvir, with or without ribavirin; 12 received ombitasvir and paritaprevir/ritonavir plus ribavirin; 17 received sofosbuvir plus daclatasvir, with or without ribavirin; and 6 received sofosbuvir plus simeprevir. The 33 healthy volunteers (male sex, 60.6%) had a median age of 42 years (range, 25-62 years) and a body mass index of 22.5 (range, 20.0-24.1).
Relationship Between T-Cell Activation and Other Variables at Baseline
CD4 + T-cell counts, CD4 + T-cell percentages, and CD4 + /CD8 + T-cell ratios were negatively correlated with the expression of both HLA-DR and CD38 in CD4 + T cells but not with other variables (Supplementary Table 2 ). However, plasma HCV RNA levels were not correlated with levels of activation markers in T cells or monocytes, microbial translocation markers, or inflammatory parameters overall (Supplementary Table 3 ) and among patients with and those without cirrhosis (data not shown).
Evolution of Immune Activation and Inflammation After HCV Eradication
Both at the end and 1 month after completing of anti-HCV therapy, there were significant decreases in the median expression of HLA-DR and CD38 on both CD4 + and CD8 + T cells. Among CD4 + T cells, median frequencies of HLA-DR expression were 3.2% (range, 0.70%-15.3%) at baseline and 2.5% (range, 0.5%-8.0%) 1 month after completion of HCV treatment; median frequencies of CD38 expression were 8.7% (range, 6.0%-40.7%) and 5.6% (range, 0.3%-6.9%), respectively; and median frequencies of both HLA-DR and CD38 expression were 2.4% (range, 0.5%-16.7%) and 0.7% (range, 0.1%-3.0%), respectively (P ≤ .001 for all comparisons). Among CD8 + T cells, median frequencies of HLA-DR expression were 3.5% (range, 1.0%-12.0%) at baseline and 2.0% (range, 0.3%-6.4%) 1 month after completion of HCV treatment; median frequencies of CD38 expression were 3.9% (range, 0.4%-48.9%) and 3.1% (range, 0.5%-13.5%), respectively, and median frequencies of both HLA-DR and CD38 expression were 2.7% (range, 0.1%-26.0%) and 0.9% (range, 0.1%-5.9%), respectively (P ≤ .001 for all comparisons). Differences in the expression of PD-1 or CD57 were not significantly different between baseline and 1 month after completion of HCV treatment. However, except for the expression of HLA-DR on CD4 + and CD8 + T cells, these values remained significantly higher than those found in healthy volunteers ( Figure 1 and Table 2 ).
Furthermore, there were significant reductions in the median proviral HIV DNA load (from 3.16 log 10 copies/10 6 PBMCs at baseline [range, 0.41-7.57 log 10 copies/10 6 PBMCs] to 2.27 log 10 copies/10 6 PBMCs [range, 0.24-5.66 log 10 copies/10 6 PBMCs] 1 month after HCV treatment completion), the median sCD14 level (from 4649 pg/mL [range, 106-67 010 pg/mL] to 2769 pg/ mL [range, 12-2516 pg/mL]), the median LPS level (from 50.1 pg/mL [range, 11.0-96.0 pg/mL] to 44.2 pg/mL [range, 5.0-63.0 pg/mL]), the 16S rDNA level (from 5.11 log 10 copies/mL [range, 4.39-6.35 log 10 copies/mL] to 4.75 log 10 copies/mL [range, 2.50-6.06 log 10 copies/mL]), and the D-dimer level (from 0.53 μg/mL [range, 0.01-5.63 μg/mL] to 0.15 μg/mL [range, 0.01-5.61 μg/ mL]; P < .001 for all comparisons). Differences in IL-6 and hs-CRP plasma levels between baseline and 1 month after HCV treatment completion were not significantly different. Although there were no differences in the plasma levels of 16S rDNA, IL-6, and D-dimers between patients who completed HCV treatment and healthy volunteers, the concentrations of sCD14, LPS, and hs-CPR in the former group remained well above those in the latter group (Table 2) . These changes were similar in patients without and those with cirrhosis ( Figure 2 and Supplementary Table 4) . ; P = .016). However, neither the cirrhosis frequency nor the frequency of CD38 expression among CD4 + T cells at baseline were associated with changes in the CD4 +/ CD8 + T-cell ratio between baseline and 6 months after the end of HCV treatment in the logistic regression model.
DISCUSSION
The fact that HCV coinfection induces a higher level of immune activation in HIV-infected patients was inferred from comparison of immune activation levels in monoinfected and coinfected patients. Only the study by Gonzalez et al [17] has shown a decreased frequency of CD38 expression on CD8 + T cells among patients (n = 14) who achieved SVR. Our study assessed the medium-term (ie, 1 month after HCV treatment cessation) impact of HCV eradication due to interferon-free regimens on several parameters related to immune activation and immune recovery in a large group of HIV/HCV-coinfected patients. In addition to a significant reduction in CD38 and HLA-DR expression on CD4 + and CD8 + T cells, there were decreases in levels of proviral HIV DNA, sCD14, microbial translocation markers, and D-dimers after the eradication of HCV infection. Although there were not quantitative correlations between the decrease in proviral HIV DNA load and the expression of HLA-DR and CD38 on both CD4 + and CD8 + T cells, it might be hypothesized that both events might be related. In HIV/HCVcoinfected patients, HCV eradication has proven to be beneficial not only in terms of the liver-related mortality rate and fibrosis regression, but also with regard to decreases in the frequencies of HIV disease progression, non-AIDS-related events, and non-liver-related mortality [26] [27] [28] [29] [30] . Almost certainly, a large proportion of this benefit is due to the reduction in the level of immune activation, given its key role in driving HIV-1 disease and non-AIDS-defining events in this population [31, 32] . By contrast, the expression of immune dysfunction (PD-1) and immune senescence (CD57) markers on both CD4 + and CD8 + T cells, as well as the IL-6 and hs-CRP plasma levels, did not change after SVR, suggesting that HCV has a limited or null influence on them in HIV/HCV-coinfected patients.
On the other hand, based on the adverse effect that HCV has on immune recovery among HIV-infected patients initiating ART [33] [34] [35] , we hoped that the eradication of HCV would contribute to restoring immunologic parameters in these patients. However, the achievement of SVR did not translate into an increased CD4 + T-cell count, CD4 + T-cell percentage, or CD4 + /CD8 + T-cell ratio. In this regard, a limitation of our study may be the limited number of patients with very low CD4 + T-cell counts and CD4 + /CD8 + T-cell ratios included in the study. It would be necessary to evaluate a larger sample of such patients to state with confidence that improvement in these parameters should not be expected in very immunosuppressed HIV-infected patients after the eradication of HCV. However, this is in concordance with results of a previous retrospective study by Saracino et al [29] , in which SVR did not seem to alter the rate of long-term improvements in the CD4 + T-cell count and CD4 + /CD8 + T-cell ratio in HIV/HCV-coinfected patients receiving ART. This is particularly worrying in HIV-infected patients who did not achieve significant immune recovery despite consistent HIV suppression, since they have shown higher rates of morbidity and mortality due to AIDS-defining and non-AIDS-defining events [36] .
Our study has other limitations, one of which is that the follow-up period was limited to 1 month after finishing HCV treatment. Data from a longer follow-up period would have reinforced the conclusions. However, the concordance between values at the end of treatment and those 1 month later allows us to be confident that these findings are immunologically relevant. Likewise, the inclusion of patients who did not achieve SVR would be very informative, but it would currently be very difficult to do so because of the elevated rate of response to the direct-acting antiviral agents.
In conclusion, our data suggest that the eradication of HCV infection in HIV/HCV-coinfected patients results in significant decreases not only in immune activation of CD4 + and CD8 + T cells, but also in levels of proviral HIV DNA, microbial translocation markers, sCD14, and D-dimers. It supports the use of HCV treatment in all HIV/HCV-coinfected patients regardless of fibrosis stage, with the sole exception of decompensated cirrhosis. 
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